

S 621

Safe Prescribing Act of 2013

Congress: 113 (2013–2015, Ended)

Chamber: Senate

Policy Area: Crime and Law Enforcement

Introduced: Mar 20, 2013

Current Status: Read twice and referred to the Committee on the Judiciary.

Latest Action: Read twice and referred to the Committee on the Judiciary. (Mar 20, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/senate-bill/621>

Sponsor

Name: Sen. Manchin, Joe, III [D-WV]

Party: Independent • **State:** WV • **Chamber:** Senate

Cosponsors (9 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Feinstein, Dianne [D-CA]	D · CA		Mar 20, 2013
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Mar 20, 2013
Sen. Kirk, Mark Steven [R-IL]	R · IL		Mar 20, 2013
Sen. Rockefeller, John D., IV [D-WV]	D · WV		Mar 20, 2013
Sen. Schumer, Charles E. [D-NY]	D · NY		Mar 20, 2013
Sen. Nelson, Bill [D-FL]	D · FL		Apr 18, 2013
Sen. Rubio, Marco [R-FL]	R · FL		Apr 18, 2013
Sen. Klobuchar, Amy [D-MN]	D · MN		Jul 29, 2013
Sen. Harkin, Tom [D-IA]	D · IA		Oct 16, 2013

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	Senate	Referred To	Mar 20, 2013

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

Bill	Relationship	Last Action
113 HR 1285	Related bill	Apr 15, 2013: Referred to the Subcommittee on Crime, Terrorism, Homeland Security, And Investigations.

Safe Prescribing Act of 2013 - Amends the Controlled Substances Act to remove dihydrocodeinone (hydrocodone) from classification as a schedule III controlled substance.

Directs the Attorney General to immediately allow manufacturers and distributors to store hydrocodone combination products in accordance with the physical security requirements for schedule III, IV, and V controlled substances for three years beginning on the date of enactment of this Act.

Requires the Comptroller General to submit a report on the reclassification of hydrocodone products under this Act, including: (1) an assessment of the degree to which the reclassification of such products under this Act impacts the ability of patients with legitimate medical needs, particularly those in rural areas and nursing home facilities, to access adequate pain management; and (2) recommendations necessary to address any issues relating to patient access to adequate pain management.

Actions Timeline

- **Mar 20, 2013:** Introduced in Senate
- **Mar 20, 2013:** Read twice and referred to the Committee on the Judiciary.